Posted on March 8th, 2009 by
A recommendation for use of the Oncotype DX® test has been added to the 2008 breast cancer treatment guidelines from the National Comprehensive Cancer Network (NCCN). According to the guidelines, Oncotype DX may be used to guide chemotherapy decisions among certain women with node-negative, hormone receptor-positive, HER2-negative breast cancer.
Although chemotherapy is recommended for many women with early-stage breast cancer, the benefit of chemotherapy varies. Identifying in advance those women who are most likely to benefit from chemotherapy may allow for more individualized treatment. This would allow women who are unlikely to benefit from chemotherapy to avoid the toxic effects of treatment.
Oncotype DX is a genomic test that predicts the likelihood of a cancer recurrence, the likelihood of benefit from chemotherapy, and the likelihood of survival in patients with newly diagnosed breast cancer that has not spread to the lymph nodes (node-negative) and is hormone receptor-positive. Oncotype DX evaluates the activity of 21 genes from a sample of the patient’s cancer to determine the patient’s Recurrence Score. The Recurrence Score ranges from 0 to 100, with a higher score indicating a greater risk of recurrence.
The NCCN is an alliance of 21 leading cancer centers. The NCCN has developed treatment guidelines for most types of cancer, including breast cancer.
The NCCN has added Oncotype DX as an option in the management of certain women with node-negative, hormone receptor-positive, HER2-negative breast cancer. For women with a low Recurrence Score, adjuvant therapy may involve hormonal therapy alone. Women with a higher Recurrence Score may be candidates for chemotherapy in addition to hormonal therapy.
Women with newly diagnosed, early-stage, hormone receptor-positive breast cancer may wish to discuss the Oncotype DX test with their physician.
Reference: Genomic Health Press Release. Genomic Health reports recommendation of Oncotype DX® in National Comprehensive Cancer Network Guidelines. Available at: http://investor.genomichealth.com/ReleaseDetail.cfm?ReleaseID=284249 (Accessed January 3, 2008).
Copyright © 2010 CancerConsultants. All Rights Reserved.
Tags: UNM CC Features
You must be logged-in to the site to post a comment.